Table 2.

Weekly symptom scores from the pre-treatment phase till the completion of the study

	Baseline, mean ± SEM (n)	At week 1, mean ± SEM (n)	At week 2, mean ± SEM (n)	At week 3, mean ± SEM (n)	At week 4, mean ± SEM (n)	p value*
Total abdominal symptom score
Famotidine group	15.96±1.58 (23)	6.35±0.79 (23)	5.35±0.69 (23)	4.22±0.75 (23)	3.82±0.67 (22)	<0.0001
Placebo group	14.46±1.47 (24)	7.35±0.99 (23)	5.29±0.72 (21)	4.55±0.69 (20)	3.50±0.72 (20)	<0.0001
EPS symptom score
Famotidine group	2.87±0.34 (23)	2.04±0.31 (23)	1.65±0.34 (23)	1.04±0.26 (23)	1.09±0.23 (22)	<0.0001
Placebo group	2.42±0.32 (24)	2.09±0.38 (23)	1.43±0.28 (21)	1.20±0.26 (20)	0.95±0.25 (20)	0.007
PDS symptom score
Famotidine group	3.91±0.53 (23)	3.00±0.40 (23)	2.52±0.34 (23)	1.96±0.35 (23)	1.59±0.29 (22)	0.0009
Placebo group	3.96±0.51 (24)	3.43±0.35 (23)	2.71±0.36 (21)	2.30±0.33 (20)	1.70±0.38 (20)	0.002

^*p value, difference between pre- and post-4 week treatment scores. EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.